- Home
- SILO vs GTBP Comparison
SILO vs GTBP Comparison
Compare SILO & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILO | GTBP |
|---|---|---|
| Founded | 2010 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 8.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SILO | GTBP |
|---|---|---|
| Price | $0.38 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 186.2K | ★ 2.0M |
| Earning Date | 11-13-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $72,102.00 | N/A |
| Revenue This Year | $1.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.54 |
| 52 Week High | $3.37 | $3.85 |
Technical Indicators
Market Signals| Indicator | SILO | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 47.68 |
| Support Level | $0.33 | $0.76 |
| Resistance Level | $0.43 | $0.87 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 48.67 | 20.45 |
Price Performance
Historical ComparisonAbout SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.